<DOC>
	<DOC>NCT02933502</DOC>
	<brief_summary>An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis</brief_summary>
	<brief_title>Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product</brief_title>
	<detailed_description>- Evaluate the potential of DSXS topical product to suppress HPA axis function in patients with moderate to severe scalp psoriasis. - Evaluate the efficacy parameters and adverse event (AE) profiles of DSXS topical product administered to patients with moderate to severe scalp psoriasis.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male or nonpregnant, nonlactating females 1217 years of age. Females who are pregnant, nursing, planning to become pregnant during the duration of the study, or if of childbearing potential and sexually active and not prepared to use appropriate contraceptive methods to avoid pregnancy.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>